1.Mechanisms of microRNA action in rectal cancer radiotherapy.
Lili ZHU ; Mojin WANG ; Na CHEN ; Yujie ZHANG ; Tao XU ; Wen ZHUANG ; Shuomeng XIAO ; Lei DAI
Chinese Medical Journal 2022;135(17):2017-2025
Preoperative neoadjuvant chemoradiotherapy, combined with total mesorectal excision, has become the standard treatment for advanced localized rectal cancer (RC). However, the biological complexity and heterogeneity of tumors may contribute to cancer recurrence and metastasis in patients with radiotherapy-resistant RC. The identification of factors leading to radioresistance and markers of radiosensitivity is critical to identify responsive patients and improve radiotherapy outcomes. MicroRNAs (miRNAs) are small, endogenous, and noncoding RNAs that affect various cellular and molecular targets. miRNAs have been shown to play important roles in multiple biological processes associated with RC. In this review, we summarized the signaling pathways of miRNAs, including apoptosis, autophagy, the cell cycle, DNA damage repair, proliferation, and metastasis during radiotherapy in patients with RC. Also, we evaluated the potential role of miRNAs as radiotherapeutic biomarkers for RC.
Humans
;
MicroRNAs/metabolism*
;
Neoplasm Recurrence, Local
;
Rectal Neoplasms/pathology*
;
Neoadjuvant Therapy
;
Radiation Tolerance/genetics*
2.Temporal and spatial stability of the EM/PM molecular subtypes in adult diffuse glioma.
Jing FENG ; Zheng ZHAO ; Yanfei WEI ; Zhaoshi BAO ; Wei ZHANG ; Fan WU ; Guanzhang LI ; Zhiyan SUN ; Yanli TAN ; Jiuyi LI ; Yunqiu ZHANG ; Zejun DUAN ; Xueling QI ; Kai YU ; Zhengmin CONG ; Junjie YANG ; Yaxin WANG ; Yingyu SUN ; Fuchou TANG ; Xiaodong SU ; Chuan FANG ; Tao JIANG ; Xiaolong FAN
Frontiers of Medicine 2023;17(2):240-262
Detailed characterizations of genomic alterations have not identified subtype-specific vulnerabilities in adult gliomas. Mapping gliomas into developmental programs may uncover new vulnerabilities that are not strictly related to genomic alterations. After identifying conserved gene modules co-expressed with EGFR or PDGFRA (EM or PM), we recently proposed an EM/PM classification scheme for adult gliomas in a histological subtype- and grade-independent manner. By using cohorts of bulk samples, paired primary and recurrent samples, multi-region samples from the same glioma, single-cell RNA-seq samples, and clinical samples, we here demonstrate the temporal and spatial stability of the EM and PM subtypes. The EM and PM subtypes, which progress in a subtype-specific mode, are robustly maintained in paired longitudinal samples. Elevated activities of cell proliferation, genomic instability and microenvironment, rather than subtype switching, mark recurrent gliomas. Within individual gliomas, the EM/PM subtype was preserved across regions and single cells. Malignant cells in the EM and PM gliomas were correlated to neural stem cell and oligodendrocyte progenitor cell compartment, respectively. Thus, while genetic makeup may change during progression and/or within different tumor areas, adult gliomas evolve within a neurodevelopmental framework of the EM and PM molecular subtypes. The dysregulated developmental pathways embedded in these molecular subtypes may contain subtype-specific vulnerabilities.
Humans
;
Brain Neoplasms/pathology*
;
Neoplasm Recurrence, Local/metabolism*
;
Glioma/pathology*
;
Neural Stem Cells/pathology*
;
Oligodendrocyte Precursor Cells/pathology*
;
Tumor Microenvironment
3.Diagnostic diversity and heterogeneity of tumors: a real-world study of metastasis re-biopsy in advanced breast cancer.
Huimin LV ; Limin NIU ; Mengwei ZHANG ; Huiai ZENG ; Shengnan ZHAO ; Min YAN
Chinese Medical Journal 2022;135(17):2076-2082
BACKGROUND:
Re-biopsy of metastasis in advanced breast cancer (ABC) has become an international convention to assist the diagnosis and evaluation of tumor heterogeneity. This study aimed to detect diagnostic diversity and inconsistencies among estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression levels between primary and metastatic lesions.
METHODS:
We conducted a retrospective analysis of 1670 cases of ABC patients who had undergone at least one lesion re-biopsy from January 2010 to December 2018. The pathological diagnosis of biopsies, distribution of biopsy sites, and severe puncture complications at each site were collected. In addition, the inconsistency rates and related factors of ER, PR, and HER2 expression between primary and metastatic lesions were analyzed fully considering patients' demographic profiles and disease characteristics.
RESULTS:
In total, 1670 cases of breast cancer (BC) patients diagnosed by pathology underwent one to four biopsies of recurrences or metastases in different sites or at different stages during the rescue treatment, producing 2019 histopathological specimens which were analyzed in the study. Pathological diagnosis showed that eight patients had benign pathological diagnoses, 11 patients had second primary malignant tumors but without recurrences of breast cancer, and 17 patients had pathologically confirmed breast cancer recurrences combined with second primary cancer. In 1173 patients who presented ER, PR, and HER2 expressions in primary and metastatic lesions, the inconsistency rates of ER, PR, and HER2 were 17.5% (205/1173), 31.3% (367/1173), and 13.9% (163/1173), respectively. The multivariate analysis showed that the age at the onset of breast cancer or adjuvant endocrine therapy was an independent factor affecting changes in PR expression level. Except one liver puncture with local hemorrhage and two lung punctures with hemopneumothorax, no other severe puncture complications occurred in 1950 non-surgical rebiopsies.
CONCLUSIONS
The pathological diagnosis of metastasis re-biopsy of ABC was diverse, and the ER, PR, and HER2 expression levels were inconsistent between primary and metastatic lesions. Therefore, more attention should be paid to perform biopsies of relapsed and metastatic breast cancers routinely in clinical practice.
Humans
;
Female
;
Breast Neoplasms/metabolism*
;
Retrospective Studies
;
Biomarkers, Tumor/metabolism*
;
Neoplasm Recurrence, Local/pathology*
;
Receptors, Progesterone/metabolism*
;
Receptor, ErbB-2/metabolism*
;
Receptors, Estrogen/metabolism*
;
Biopsy
;
Neoplasm Metastasis
4.Tyrosine kinase A and vascular endothelial growth factor receptor 2 in the invasion and metastasis of salivary adenoid cystic carcinoma.
Xiao-lin NONG ; Yong XIA ; Yi-ping YANG ; Hai-yun QING ; Jia-quan LI ; Yan-ning LI ; Yang CAO ; Hao LI ; Qi CHEN
West China Journal of Stomatology 2010;28(4):420-429
OBJECTIVETo determine the effect of tyrosine kinase A (TrkA) and vascular endothelial growth factor receptor 2 (VEGFR2) in the invasion and metastasis of salivary adenoid cystic carcinoma (SACC).
METHODSThe expression of TrkA and VEGFR2 were detected by immunohistochemical staining in 47 cases of SACC of salivary glands. Clinical data were reviewed by multivariate prognostic analysis.
RESULTSThe positive rate of TrkA and VEGFR2 in SACC was 87.23% (41/47) and 85.11% (40/47) respectively. Express of TrkA and VEGFR2 in perineural invasion and recurrence group were higher than non-perineural invasion and non-recurrence group. Significant difference was found in microvessel density (MVD) and VEGFR2 expression within different groups (P < 0.05). MVD in perineural invasion group (25.14 +/- 2.83) was significantly higher than that in none perineural invasion group (18.81 +/- 1.33) (P < 0.05). MVD in recurrence or metastasis group (26.58 +/- 2.38) was significantly higher than that (19.06 +/- 1.39) in none recurrence nor metastasis group (P < 0.05).
CONCLUSIONPositive correlation between expression of TrkA, VEGFR2 and nerve invasion and vessel metastasis of SACC indicate that TrkA and VEGFR2 play important roles in the invasion and metastasis of SACC. It is possible that TrkA and VEGFR2 could be an aid for evaluating the prognosis of SACC patients.
Carcinoma, Adenoid Cystic ; metabolism ; pathology ; Humans ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Receptor, trkA ; metabolism ; Salivary Gland Neoplasms ; metabolism ; pathology ; Vascular Endothelial Growth Factor Receptor-2
6.Expressions of human epidermal growth factor receptor 2 and vascular endothelial growth factor in primary or recurrent metastatic breast cancers.
Zhi-kuan WANG ; Hai-yan MENG ; Chun HAN ; Jun-lan YANG
Acta Academiae Medicinae Sinicae 2010;32(4):403-406
OBJECTIVETo investigate the expressions of human epidermal growth factor receptor 2 (Her-2) and vascular endothelial growth factor (VEGF) in primary and recurrent metastatic breast cancers and explore their relationship.
METHODSThe expressions of Her-2 and VEGF in 60 primary and recurrent metastatic breast cancers were detected using immunohistochemical methods. Their relationship was analyzed.
RESULTSThe positive rates of Her-2 and VEGF in the recurrent metastatic breast cancer were 40.00% and 53.33%, respectively, which were significantly higher than that in the primary breast cancer (18.33% and 31.67%) (P < 0.05). The total diversify rates of Her-2 and VEGF were 28.33% and 35.00%, respectively. Her-2 and VEGF expressions were significantly correlated between the primary and the recurrent metastatic breast cancers( P < 0.05).
CONCLUSIONSHer-2 and VEGF may play synergic roles in the occurrence and development of breast cancer. Over-expressions of Her-2 and VEGF predict poor prognosis.
Adult ; Aged ; Breast Neoplasms ; metabolism ; pathology ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; metabolism ; Prognosis ; Receptor, ErbB-2 ; metabolism ; Vascular Endothelial Growth Factor A ; metabolism
7.High aldehyde dehydrogenase 1A1 (ALDH1A1) expression correlated with risk of lymph node metastasis in papillary thyroid carcinoma.
Changli YUE ; Xiaoli ZHAO ; Cheng TIAN ; Yulan JIN ; E-mail: JINYULAN.LOVE@163.COM. ; Honggang LIU ;
Chinese Journal of Pathology 2015;44(7):490-494
OBJECTIVETo investigate the relationship between ALDH1A1 expression and lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC).
METHODSOne hundred and fifty-three paraffin-embedded specimens of PTC treated in the Beijing Tongren Hospital of Capital Medical University were selected from January 2006 to December 2013. The expression of ALDH1A1 was detected in both tumor tissues and adjacent non-tumor tissues by immunohistochemistry and several clinicopathological parameters (size, bilaterality, multifocality, tumor border and extrathyroidal extensions) were assessed by HE staining. The correlation of ALDH1A1 expression with LNM was analyzed.
RESULTSIn 153 cases of PTC, there were 82 cases with LNM, 126 cases with high ALDH1A1 expression in tumor tissues, and 112 cases with high ALDH1A1 expression in adjacent non-tumor tissues. On univariate analysis, patient age < 45 years, tumor size of 10 mm or more, invasive tumor border, and high ALDH1A1 expression in tumor tissues predicted LNM in PTC (P < 0.05), whereas gender, bilaterality, multifocality, extra-thyroidal extensions and high ALDH1A1 expression in adjacent non-tumor border did not (P > 0.05). On multivariate analysis, invasive tumor border, high ALDH1A1 expression in tumor tissues were found to be independent predictive factors for LNM in PTC (P < 0.05). After a follow-up of 42 months (median time), four patients developed locoregional recurrences, but no distance recurrence or disease related death were seen in 82 patients of follow up. The estimated 5-year locoregional recurrence was 4.88%. Of these four logcoregional recurrences, three involved lymph nodes and one involved the remaining thyroid. The ALDH1A1 expression in tumor tissues was high in all of recurrence cases.
CONCLUSIONHigh ALDH1A1 expression in tumor tissues is correlated with lymph node metastasis in PTC and may be used as an independent predictive factor of LNM, and may improve treatment and follow-up strategies for PTC.
Aldehyde Dehydrogenase ; metabolism ; Carcinoma ; metabolism ; pathology ; Carcinoma, Papillary ; Humans ; Immunohistochemistry ; Lymph Nodes ; pathology ; Lymphatic Metastasis ; Multivariate Analysis ; Neoplasm Recurrence, Local ; Risk Factors ; Thyroid Neoplasms ; metabolism ; pathology
8.Expression of Ki-67 antigen in ameloblastoma and its clinical significance.
Bo HAN ; Longjiang LI ; Hu WANG
West China Journal of Stomatology 2003;21(2):153-154
OBJECTIVEThe expression of Ki-67 antigen of ameloblastoma was examined in order to investigate the different proliferation activity of histological variants of ameloblastoma and its clinical significance.
METHODS70 cases of different histological specimen of ameloblastoma were analyzed by immunohistochemical method using Ki-67 antibody. The Label Index was calculated in percentage of Ki-67 positive cells after examined with an image analysis system.
RESULTSThe results showed that the Labeled Index in malignant ameloblastoma was the highest 14.72% +/- 2.87%. The Labeled Index in solid ameloblastoma was in the middle, among which the follicular 4.42% +/- 1.05% was higher than the plexiform 3.64% +/- 1.23%. The Labeled Index in mono-cystic ameloblastoma was the lowest 2.21% +/- 1.09%.
CONCLUSIONThe results demonstrated that the proliferation activity varied according to the histological pattern of ameloblastoma. The prognosis with different proliferation activity was also varied accordingly.
Ameloblastoma ; metabolism ; pathology ; Humans ; Image Processing, Computer-Assisted ; Jaw Neoplasms ; metabolism ; pathology ; Ki-67 Antigen ; biosynthesis ; Neoplasm Recurrence, Local ; Odontogenic Tumors ; metabolism ; pathology
9.Pediatric pilocytic astrocytoma with monomorphous pilomyxoid features and plexiform pattern: report of a case.
Chinese Journal of Pathology 2011;40(8):565-566
Astrocytoma
;
metabolism
;
pathology
;
surgery
;
Brain Neoplasms
;
metabolism
;
pathology
;
surgery
;
Child, Preschool
;
Diagnosis, Differential
;
Ependymoma
;
metabolism
;
pathology
;
Female
;
Follow-Up Studies
;
Glial Fibrillary Acidic Protein
;
metabolism
;
Humans
;
Neoplasm Recurrence, Local
;
Neoplasm Staging
;
Neurofibroma, Plexiform
;
metabolism
;
pathology
;
S100 Proteins
;
metabolism
;
Vimentin
;
metabolism
10.Phyllodes tumor of breast.
Chinese Journal of Pathology 2006;35(11):687-690
Actins
;
metabolism
;
Adult
;
Breast Neoplasms
;
metabolism
;
pathology
;
surgery
;
Diagnosis, Differential
;
Female
;
Humans
;
Immunohistochemistry
;
Middle Aged
;
Neoplasm Recurrence, Local
;
Phyllodes Tumor
;
metabolism
;
pathology
;
surgery
;
Vimentin
;
metabolism